Skip to main content
Premium Trial:

Request an Annual Quote

Ciphergen Reports Strong Revenue Growth, Slightly Smaller Loss in Q4

NEW YORK, Feb.14 - Ciphergen Biosystems reported strong growth in revenues and R&D spending during the fourth quarter of 2002 today, along with a slightly smaller net loss.


Revenues for the quarter ended Dec. 31 increased to $13.6 million, up from $7.3 million during the same period the year before.


R&D spending during the quarter was $6.1 million, up from $4.0 million during the year-ago period.


Net losses decreased slightly, from $7.1 million or $.27 per share to $6.7 million or $.25 per share.


Ciphergen said it had $42.5 million in cash, cash equivalents, and investments in securities as of Dec. 31, 2002.

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.